Medical Centre Pratia Clinic EOOD
- Address
- Ulitsa Doktor Siyko Siev 27, 5500 Lovech, Bulgaria
Respiratory Function and Asthma Care
The research at Medical Centre Pratia Clinic EOOD focuses on improving outcomes for patients with asthma and Chronic Obstructive Pulmonary Disease through advanced inhaler therapies and optimized treatment regimens.
- Evaluation of triple inhaler therapy versus dual therapy
- Assessment of lung function improvements using FEV1 measurements
- Reduction of moderate and severe exacerbation rates
- Comparison of new bronchodilator combinations for safety and tolerability
Ongoing studies aim to provide clearer guidance for clinicians and enhance quality of life for individuals living with chronic respiratory conditions.
Viral Respiratory Infection Prevention
Trials at the centre address the burden of Respiratory Syncytial Virus, human metapneumovirus and seasonal influenza in older adults, evaluating novel vaccine candidates and high‑dose formulations.
- Vaccination strategies for adults aged 60 and over
- Efficacy of high‑dose trivalent influenza vaccine compared with standard vaccine
- Development of RSV and hMPV virus‑like particle (VLP) vaccines
- Safety monitoring of single‑dose immunizations during the first respiratory season
The goal is to reduce severe respiratory infections and hospitalizations by establishing effective preventive measures.
Innovative Biologic and Inhaled Therapies
The site investigates cutting‑edge biologics such as anti‑TSLP antibody, depemokimab and tozorakimab, as well as novel inhaled compounds, to address unmet needs in severe asthma and COPD with type‑2 inflammation.
- Targeting type‑2 inflammatory pathways in COPD exacerbations
- Exploring TSLP inhibition for uncontrolled asthma management
- Assessing long‑acting biologic agents for sustained symptom control
- Pharmacokinetic and immunogenicity profiling of new inhaled molecules
These investigations seek to expand therapeutic options and improve disease control for patients who remain symptomatic despite standard care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 9 therapeutic areas and 15 of 39 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 11 by active trials.
- 1Chiesi Farmaceutici S.p.A.2active
lock +10 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Chiesi Farmaceutici S.p.A.5trials
lock +5 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medical Centre Pratia Clinic EOOD
lock Showing 1 of 30 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| 22104: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2b/3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Active Psoriatic Arthritis | Acelyrin Inc. | Phase IV | Not Recruiting | Apr 2023 | Oct 2024 |
IMP list
lock Showing 1 of 39 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Formoterol Fumarate Dihydrate | 4 | Unknown | 2021-04-29 | 2026-04-13 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.